Biotechnology company developing cancer immunotherapies that activate natural killer (NK) cells
Biotechnology company developing cancer immunotherapies that activate natural killer (NK) cells. Its proprietary INABLR antibody-discovery platform supports antibody discovery and development. Lead candidate ZM008 blocks NK-cell inhibitory signals to enable an anti-tumor immune response and is being evaluated in clinical trials.